Kottayam MCH collapse: Bindu's daughter in recovery, cabinet recommends job for son
According to her father Visruthan, doctors informed that there was nothing to worry about his daughter's health.
Tired of too many ads? go ad free now
The 21-year-old was admitted to the MCH for treatment for pain in her backbone.
The 11-hour surgery was completed on Wednesday evening, and she was admitted to the intensive care unit. She will be shifted to a special ward after being put under observation for two days.
Meanwhile, the state cabinet on Thursday sanctioned Rs 10 lakh as financial assistance from the chief minister's distress relief fund (CMDRF) to Bindu's family.
The cabinet also recommended Travancore Devaswom Board offer her son Navaneeth a suitable job.
When told about the govt's decision to provide the compensation and a job to Navaneeth, Visruthan said that his focus at the moment is his daughter's treatment. He also expressed optimism in the promises made by the govt. "I'm getting everything from the govt side. Whatever they promised to give the family will be given," said Visruthan, who expressed confidence in the govt.
Meanwhile, Congress leader Chandy Oommen told reporters that the compensation of Rs 10 lakh was insufficient. He said that Rs 25 lakh was sought as compensation as the death was due to a lapse on the part of the govt. The MLA had earlier handed over Rs 5 lakh to the family. Bindu's employer too extended a cheque of Rs 1 lakh to the family and promised to give an amount of Rs 5,000 every month.
Bindu was killed after a building at the Kottayam MCH collapsed last Thursday. She was accompanying her daughter who was admitted to the MCH.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 hours ago
- New Indian Express
Remote centres outside Kerala force candidates to drop out of NEET-PG
THIRUVANANTHAPURAM/KOCHI: With just two days remaining for the National Eligibility Entrance Test-Postgraduate (NEET-PG), on August 3, many medical graduates are shocked to get examination centres outside the state — in Andhra Pradesh, Tamil Nadu and Karnataka. Many candidates had carefully chosen cities near their residences as preferred centres during the application process. However, many were stunned to be assigned locations hundreds of kilometres away. 'I'm not appearing for the exam this time. I've been allotted a centre in Telangana, and I'm eight months pregnant. The travel and stay costs are too high for me and my family,' said Dr Kavitha (name changed), a candidate from Thiruvananthapuram. 'Other young mothers in my batch are opting out too. We've paid Rs 4,000 for the application, and now we're forced to abandon the attempt.' Surveys conducted by several junior doctor associations revealed that approximately 1,000 applicants from Kerala were given centres outside the state. The uncertainty over exact venue details — only disclosed two days prior to the exam on July 31 — adds to the logistical nightmare. 'If I had received Kollam as my centre, I could reach anywhere nearby without issues. But with a location like Visakhapatnam, I don't even know how close the centre will be to a hotel. How do we plan ahead?' said Dr Ashik Basheer, state president of the General Practitioners Association. Candidates have also voiced concerns over inflated travel and accommodation prices.
News18
3 hours ago
- News18
Weight Loss Drug Mounjaro May Help Diabetics Live Longer, Protect The Heart & Kidneys: Eli Lilly
Last Updated: The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company said In a major development that could shift the way obesity is treated globally, Eli Lilly's weight loss and type 2 diabetes drug tirzepatide, sold as the brands Mounjaro and Zepbound, has been shown to significantly reduce the risk of serious cardiovascular complications, including heart failure and chronic kidney disease. Eli Lilly on Thursday announced results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase 3 cardiovascular outcomes trial comparing two incretin therapies—Mounjaro and Trulicity—in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. Trulicity—made by Lilly—is not insulin, but it helps the body release insulin more effectively after meals. About tirzepatide Tirzepatide works by mimicking two gut hormones—GIP and GLP-1—that regulate appetite, insulin response, and energy use. This dual-action mechanism sets it apart from earlier drugs and is believed to drive both its weight loss and cardiometabolic benefits. In the SURPASS-CVOT study, Mounjaro (tirzepatide) was shown to be as safe as Trulicity in preventing serious heart issues like heart attack, stroke, or heart-related death. While not the focus of the study, Mounjaro also showed better results in lowering blood sugar (A1C), reducing weight, improving kidney function, and lowering overall death risk. The trial included over 13,000 people across 30 countries and ran for more than 4.5 years, making it the largest and longest study on tirzepatide so far, the company claimed. These results hold significance for India, as the American pharma giant launched the drug here on March 20, and since then, the drug has seen rapid uptake. In just three months, sales soared to Rs 12.6 crore in May, tripling from March, according to Pharmatrac data. Priced at Rs 4,375 (5 mg) and Rs 3,500 (2.5 mg) per vial, Mounjaro's monthly cost ranges from Rs 14,000-17,500, nearly 80% cheaper than US prices. While the results from the trial are promising, detailed results for SURPASS-CVOT will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in September and published in a peer-reviewed journal. Lilly said it plans to submit the data to global regulatory authorities by the end of this year. 'Cardiovascular disease remains the leading cause of death among people living with type 2 diabetes," Kenneth Custer, executive vice president and president, Lilly Cardiometabolic Health, wrote in the press release issued by the drugmaker. 'The SURPASS-CVOT results show that Mounjaro preserved the cardioprotective benefit of Trulicity, a GLP-1 receptor agonist, while providing additional benefits, including greater kidney protection and a reduced overall risk of death. These findings strengthen the case for Mounjaro as a potential front-line treatment for people with type 2 diabetes and cardiovascular disease." Findings of the study In the trial, the risk of cardiovascular death, heart attack, or stroke was 8% lower for Mounjaro vs Trulicity, meeting the prespecified criteria for non-inferiority. In simple words, Mounjaro reduced the risk of heart-related problems (heart attack, stroke, or heart death) by 8% compared to Trulicity. It also lowered the overall risk of death by 16%. A separate analysis using past trial data suggested Mounjaro may reduce heart risks by 28% and death risk by 39% compared to a theoretical placebo. In people with serious kidney problems, Mounjaro slowed kidney decline more effectively than Trulicity over three years. In the trial, Mounjaro helped patients improve their blood sugar (A1C), lose more weight, and showed better heart-related health markers like cholesterol and blood pressure compared to Trulicity. Both medicines had similar safety profiles. The most common side effects were stomach-related issues like nausea or diarrhoea, which were mostly mild and got better over time. However, 13.3% of people on Mounjaro stopped treatment due to side effects, compared to 10.2% on Trulicity. Get breaking news, in-depth analysis, and expert perspectives on everything from politics to crime and society. Stay informed with the latest India news only on News18. Download the News18 App to stay updated! view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
3 hours ago
- Hans India
Human milk bank offering lifeline to fragile newborns
Tirupati: A silent revolution has been unfolding at the Government Maternity Hospital in Tirupati, one drop at a time. The Rotary Human Milk Bank, launched just over a year ago on April 3, 2024, has emerged as a vital support system for fragile newborns unable to receive their mother's milk, while simultaneously fostering greater public awareness about milk donation. This initiative holds particular significance as the theme for this year's World Breastfeeding Week (August 1 to 7) is 'Prioritise Breastfeeding: Create Sustainable Support Systems'. Established with a generous Rs 30 lakh contribution from the Rotary Club of Tirupati, the bank's mission is clear: to ensure every infant receives safe, life-sustaining nourishment during their most vulnerable phase, irrespective of their mother's health. With approximately 1,200 deliveries annually at the hospital, the need for such a facility was evident. Many babies are born prematurely or face complications that hinder breastfeeding, often leading to reliance on formula or unprocessed milk, both of which carry potential health risks. "Breast milk is a divine gift for a newborn. It strengthens the baby's body and boosts immunity," explained Dr B Manohar, Head of Paediatrics at SV Medical College. "However, some mothers - such as those who have undergone premature delivery or had complications during childbirth - may not be able to produce sufficient milk. For such babies, the Human Milk Bank is a great help." The milk bank bridges this gap by collecting surplus milk from healthy, lactating mothers. This donated milk undergoes rigorous safety protocols: potential donors are screened for infections like HIV, Hepatitis B (HBsAg), and Hepatitis C (HCV), often during their admission for delivery. "Mothers who are healthy and lactating in abundance can donate their excess milk. This milk is thoroughly tested, pasteurised, stored hygienically, and given to needy newborns. When you donate your milk, you may be saving a newborn's life," Dr Manohar added. K Bhuvaneswari, Manager of the milk bank, noted the efforts to sensitize mothers post-delivery on the importance of donation. While many mothers are willing, we still face resistance from their elders, especially in-laws, who discourage them, she said. Despite these challenges, awareness is clearly on the rise. From April to December 2024, 643 mothers donated milk, and an additional 459 mothers contributed from January 2025 to date. One mother even garnered appreciation from the district collector for donating over 2,000 ml. The Human Milk Bank provides approximately 30 ml of breast milk daily to each infant in need, particularly those admitted to the neonatal ICU. Its benefits have also extended to supporting children recovering from surgeries at the Padmavathi Children's Heart Centre. This facility has undeniably become a crucial component of neonatal care within the hospital, immensely benefiting numerous infants. Beyond the recipients, mothers who donate also experience advantages. Experts suggest that breast milk donation helps regulate supply, prevents engorgement, and contributes to overall maternal well-being.
